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TheMDM2oncoprotein playsmultiple regulatory roles in the
control of p53-dependent gene expression. A picture of MDM2
is emerging where structurally discrete but interdependent
functional domains are linked through changes in conforma-
tion. The domain structure includes: (i) a hydrophobic pocket at
theN terminus ofMDM2 that is involved inboth its transrepres-
sor and E3-ubiqutin ligase functions, (ii) a central acid domain
that recognizes a ubiquitination signal in the core DNA binding
domain of p53, and (iii) a C-terminal C2H2C4 RING finger
domain that is required for E2 enzyme-binding and ATP-de-
pendent molecular chaperone activity. Here we show that the
binding affinity of MDM2s hydrophobic pocket can be regu-
lated through the RING finger domain and that increases in
pocket affinity are reflected by a gain in MDM2 transrepressor
activity. Thus, mutations within the RING domain that affect
zinc coordination, but not one that inhibits ATP binding, pro-
duce MDM2 proteins that have a higher affinity for the BOX-I
transactivation domain of p53 and a reduced I0.5 for p53 tran-
srepression. An allostericmodel for regulation of the hydropho-
bic pocket is supported by differences in protein conformation
and pocket accessibility between wild-type and the RING
domain mutant MDM2 proteins. Additionally the data demon-
strate that the complex relationship between different domains
of MDM2 can impact on the efficacy of anticancer drugs
directed toward its hydrophobic pocket.
The tumor suppressor protein p53 is a transcription factor
that plays a key role in the control of pathways that protect cells
from malignant transformation (1, 2). As such, p53 is the most
frequently inactivated protein in human cancers (3). In
response to cellular stress, p53 protein levels are elevated by a
decrease in its rate of degradation, and this increase in levels is
accompanied by changes in the status of p53 post-translational
modifications. Together, elevated levels of p53 and activating
post-translational modifications induce its sequence-specific
DNA binding and transcriptional activity leading to changes in
gene expression that classically result in either cell cycle arrest
or apoptosis (4).
Under non-stressed conditions p53 is tightly controlled by
the MDM2 oncoprotein through an autoregulatory feedback
loop (5–8). MDM2 plays multiple regulatory roles in the con-
trol of p53-dependent gene expression. Originally identified as
a transrepressor of p53-mediated transcription (5, 8), MDM2
was subsequently shown to control the steady-state levels of
p53 in unstressed cells by acting as a RING finger domain E34-
ubiquitin ligase (9, 10). More recently MDM2 has also been
implicated in the control of p53 translation (11) and in addition
has been shown to possess an ATP-dependent molecular chap-
erone activity toward p53 (12, 13). MDM2 is a multidomain
protein comprising: (i) A hydrophobic pocket at its N terminus
that binds with a high affinity to the BOX-I transactivation
domain of p53 (14). This interaction is required for both the
E3-ligase and transrepressor functions of MDM2 (15). (ii) A
central acid domain that recognizes and binds with a relatively
low affinity to a ubiquitination signal in the core of p53 (16–18).
(iii) A C-terminal C2H2C4 RING finger domain (19–21). This
domain is essential for zinc coordination and is involved in
E2-binding and the formation of RING domain dimers (22). In
addition the RING domain houses a P-Walker motif that is
required for MDM2 to act as an ATP-dependent molecular
chaperone (12, 23).
Negative regulation of p53 transcription by MDM2 involves
competition for binding to p53s N-terminal LXXLL transacti-
vation domain (BOX-I domain), thus binding of MDM2 can
occlude the binding of transcription components like the coac-
tivator p300 preventing the formation of a pre-initiation com-
plex (8, 24–27). Mutations in the p53 activation domain that
prevent MDM2 binding can attenuate MDM2-catalyzed tran-
srepression (15, 28), and peptide ligands mimicking the activa-
tion domain of p53 that bind to the N-terminal domain of
MDM2 and disrupt the MDM2:p53 protein complex in vitro
can stimulate p53-dependent gene expression in cells (27, 28).
Together these data suggest that binding of the BOX-I activa-
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required for MDM2s oncogenic functions. Recent studies have
identified a second MDM2 interaction site within the core
domain (BOX-V) of p53 (16–18, 29). The BOX-V domain
binds to the acid domain of MDM2, and, although this interac-
tion has a relatively low affinity, it is key in determining the rate
of p53 ubiquitination as it comprises part of the p53 ubiquiti-
nation signal (16).
The current study has used point mutations within critical
C2H2C4 resides of the MDM2 RING domain to uncover
cross-talk between the zinc coordinating structure and the
hydrophobic pocket of MDM2. A gain in the ability of
MDM2 to transrepress p53-dependent transcription is seen
when zinc-coordinating residues are mutated, whereas muta-
tion of a residue within the RING required for ATP binding has
no effect onMDM2mediated transrepression. Studies on puri-
fied MDM2 and p53 provide a mechanism for changes in tran-
srepressor activity by demonstrating that the C2H2C4 RING
mutants have a higher affinity for hydrophobic pocket interact-
ing ligands and proteins. Thus, the RING finger domain of
MDM2 is linked to the hydrophobic pocket through conforma-
tional changes that affect MDM2 transrepressor activity. In
addition, the efficacy of small molecules, targeted to the hydro-
phobic pocket ofMDM2, can be determined by the status of the
C2H2C4 structure.
EXPERIMENTAL PROCEDURES
Reagents and Plasmids—Antibodies used were: DO-1 (p53)
and 2A10/3G5/4B2/SMP14 (MDM2) produced in-house,
p21 was detected using AB1 (Calbiochem). Peptides, N-ter-
minal biotin-labeled plus an SGSG space (Chiron Mimo-
topes), were dissolved at 10 mg/ml in DMSO as previously
described (16). The BOX-I and 12.1 sequences are
PPLSQETFSDLWKLLP and MPRFMDYWEGLN, respec-
tively. Nutlin-3 was from Alexis Biochemicals. Ubiquitin
(U-100), UbcH5a (E2-616), and E1 (E-301) were from Boston
Biochem. pcDNA3-p53 and His-ubiquitin were a gift from
David Lane, pCMV-mycMDM2wt, pCMV-mycMDM2N,
and pCMV-MDM2Ac were provided by Aart Jochemsen.
pcDNA3-MDM2 with the human MDM2 cDNA was used
as a template to generate pcDNA3-MDM2C464A,
pcDNA3-MDM2C478S, and pcDNA3-MDM2K454A using
a QuikChange mutagenesis kit (Stratagene). The primers
were as follows: K454A, GCATTGTCCATGGCGCAACAG-
GACATC; K454Arev, GATGTCCTGTTGCGCCATGGACA-
ATGC; C464A, GGACATCTTATGGCCTGCTTTACAGCG-
GCAAAGAAGCTAAAGAAAAGG; C464Arev, CCTTTTCT-
TTAGCTTCTTTGCCGCTGTAAAGCAGGCCATAAGAT-
GTCC; C478S, GGAATAAGCCCTGCCCAGTAAGCAGAC-
AACCAATTCAAATGATTGTG; and C478Srev, CACAATC-
ATTTGAATTGGTTGTCTGCTTACTGGGCAGGGCTTA-
TTCC.
Cell Culture, Reporter Assays, and Immunoblots—H1299
cells were maintained in RPMI medium supplemented with 10%
(v/v) fetal bovine serumand incubatedat 37 °Cwith5%CO2.A375
cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% (v/v) fetal bovine serum and incubated
at 37 °C with 10% CO2. MDM2/p53/ cells were main-
tained in Dulbecco’s modified Eagle’s medium with 10% (v/v)
fetal bovine serum and 10% CO2. Upon reaching 80–90% con-
fluency the cells were transfected using Lipofectamine 2000
(Invitrogen) with the total amount of DNA for all wells kept
constant at 0.8 g. A solution was formed with (30 ng)
pGL4.10[luc2] bearing a 44-base stretch of the p21 promoter
and with 70 ng of the phRL-CMV plus p53 and MDM2 plas-
mids as detailed in the figure legends. Twenty-four hours post-
transfection, the cells were washed once in ice-cold phosphate-
buffered saline and lysed with 1 Passive Lysis Buffer (supplied
with the Dual-Luciferase Reporter Assay System from Pro-
mega). Alternatively, Nutlin was added after 24 h (as detailed in
the figure legends), and the incubation continued for a further
6 h. Afterward the Dual-Luciferase Reporter Assay was per-
formed in accordancewith themanufacturer’s instructions. For
immunoblot analysis transfected cells were lysed in Nonidet
P-40 buffer (25 mM HEPES, pH 7.5, 0.1% (v/v) Nonidet P-40,
150mMKCl, 5mM dithiothreitol, 50mMNaF), and lysates were
separated on 4–12% NuPAGE (to detect p53 modification) or
10% SDS-PAGE and transferred to nitrocellulose (16).
Ubiquitination Assay—The in vitro assay was carried out as
previously described (16). Reactions contained 25 mM HEPES,
pH 8.0, 10 mM MgCl2, 4 mM ATP, 0.5 mM dithiothreitol, 0.05%
(v/v) Triton X-100, 0.25 mM benzamidine, 10 mM creatine
phosphate, 3.5 units/ml creatine kinase, ubiquitin (2 g), E1
(50–200 nM), E2s (0.1–1 M), plus p53 purified from Esche-
richia coli (100 ng) andwere initiated by the addition of purified
human MDM2 (50 ng) in the presence or absence of either
BOX-I or Nutlin as detailed in the figure legends. p53 ubiquiti-
nation in p53/MDM2/mouse embryonic fibroblasts was
determined using a previously described method (16).
Protein Binding Assays—Recombinant human full-length
untagged MDM2 proteins and p53 protein were purified from
E. coli as previously described (12, 30). For peptide and protein
binding assays the microtiter wells were adsorbed with strepta-
vidin overnight, washed 6 with phosphate-buffered saline-
Tweenwith biotinylated peptides added for 1 h alternatively the
wells were coated with purified p53 (150 ng) as previously
described (16). Following extensive washing with phosphate-
buffered saline-Tween increasing amounts of MDM2 were
added either in the absence or presence of Nutlin (as detailed in
the figure legends). Following washing (6 washes with phos-
phate-buffered saline-Tween) MDM2 was detected using the
monoclonal antibody 2A10 and a secondary rabbit anti-mouse
horseradish peroxidase antibody the wells were developed
using ECL. The results were quantified using Fluoroskan
Ascent FL equipment (Labsystems) and analyzed with Ascent
Software.
Tryptic Digestion—wt or mutant MDM2 protein (1 g) plus
trypsin (10 ng) was incubated at 30 °C in 50 mM ammonium
bicarbonate buffer for up to 30 min. Aliquots were removed,
and the reaction was stopped by the addition of SDS sample
buffer and heating at 80 °C for 4 min. The samples were ana-
lyzed by 4–12% gradient gels (Invitrogen) and immunoblotted.
Intrinsic Fluorescence Assay—Fluorescence emission spectra
were recorded on a SPEX FLUOROMAX-3 (Jobin Yvon
Horiba) spectrofluorometer. The bandwidths for excitation
and emission were set at 5 nm, and an excitation wavelength of
295 nmwas used. Fluorescence spectrawere recorded from320
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to 450 nm in 0.5 nm steps, with an integration time of 1 s. All
experiments were carried out at 4 °C in buffer containing: 25
mM HEPES (pH 7.5), 50 mM KCl, 5% (v/v) glycerol, 10 M
ZnSO4, and 2mMdithiothreitol.MDM2wt,MDM2C464A, and
MDM2C478S used in this assay were initially preincubated on
ice for 5 min at final concentrations raging from 20 nM to 1 M
(Vtotal  0.5 ml). Each spectrum produced is the average of
three emission scans minus the average of the three blanks
(buffer) scans.
RESULTS
C2H2C4 MDM2 Mutant Proteins Have a Gain of Transre-
pressor Activity—We have recently shown that the E3-ligase
activity of MDM2 requires interactions at both the hydropho-
bic pocket and the acid domain (16). These interactions are
linked by an allosteric mechanism, with binding at the hydro-
phobic pocket favoring recognition of a p53 ubiquitination sig-
nal from its core DNA binding domain (BOX-V). This
prompted us to ask whether similar mechanisms linked other
MDM2 domains and how cooperation between domains
impacted on the proteins multifunctional nature. The RING
finger domain of MDM2 is required for both its E3-ligase and
ATP-dependent chaperone activities through binding to an
E2-ubiquitin conjugating enzyme and to ATP, respectively (12,
22). However, whether conformational changes in the RING
domain are transmitted to other MDM2 functional domains
affecting their activity remains unclear.
To study the RING domain in the context of full-length
MDM2 we first generated a number of RING finger domain
mutant constructs (Fig. 1A). Two of these, Cys464A
(MDM2C464A) and Cys478S (MDM2C478S), introduced
mutations into the C4 and H2C2 coordination sites of the
C2H2C4 structure (21), respectively, and a third, Lys454A
(MDM2K454A), is a RING domain residue, which is not
required for zinc coordination but is essential for MDM2 to
bindATP (12, 23). TheCys464Amutant was chosen because it is
the most widely studied E3-ligase-dead MDM2 RING mutant,
in addition this cysteine lies within an -helix, and structure
predication using PyMOL suggests that mutation to Ala has
little effect on the global structure of the RING or on the extent
of solvent exposure. The Cys478S mutant is similarly predicted
to have a minimal effect on the local environment, because it
lies within an irregular loop structure. To characterize these
mutants we first determined the effect of introducing the RING
mutations on E3-ligase activity using a cell-based assay. When
p53/MDM2/mouse fibroblastswere transfectedwith p53
and MDM2 together with His-tagged ubiquitin it was demon-
strated that the Lys454A mutant retained the ability to ubiquiti-
nate p53, as determined by the isolation of His-ubiquitin-con-
jugated p53 protein (Fig. 1B), whereas, as expected, the
C2H2C4 mutants were no longer able to mediate p53 modifi-
cation by ubiquitin. Although the introduction of theCysmuta-
tions is sufficient to inactivate MDM2 as an E3-ligase, they do
not affect the overall integrity of the C terminus as we have
shown that the Cys464A and Cys478S MDM2mutants retain the
ability to bind ATP, while ATP-binding activity is lost in
the Lys454A mutant (12). Thus, mutation of Cys residues in the
RING appears to specifically inactivate RING function during
ligation of ubiquitin to target substrates while leaving other
RING domain functions intact.
The various MDM2 RING finger domain mutants were
tested in a p53-dependent transcription assay to determine if
inactivation of either its E3-ligase or ATP-binding activities
affected the ability of MDM2 to repress p53-dependent tran-
scription. The ability of p53 to activate transcription was deter-
mined using the p53-responsive region of the p21-promoter to
drive luciferase expression. When human p53 was transfected
into H1299 cells (human p53 null non-small cell lung carci-
noma cells) along with the p21-reporter a characteristic activa-
tion of the promoter was detected (Fig. 1C), coexpression of
wild-type MDM2 in a titrative manner led to a progressive
decrease in reporter activity indicative of transrepression, with
an I0.5 in the region of 300 ng of MDM2 plasmid (150 ng of p53
plasmid (Fig. 1C)). All the RING mutants were expressed to a
similar level and were able to inhibit p53-dependent transcrip-
tion, however, both the Cys mutants displayed a gain of tran-
srepressor function with an I0.5 of 75 ng for MDM2C464A
and150 ng for MDM2C478S. In contrast, mutation of Lys454
did not enhance the repressor activity of MDM2, and like the
wild-type protein, this mutant had an I0.5 of around 300 ng.
Similarly, although a titration of p53 could overcome transre-
pression imposed by a fixed amount of wild-type MDM2 and
the Lys454A mutant, there was a significant reduction in the
ability of p53 to overcome the effects of the Cys464A andCys478S
mutants (Fig. 1D). To determine whether comparison of an
Ala-substituted Cys to a Ser-substituted Cys underlined the
apparent difference in potency of the MDM2C464A and
MDM2C478S mutants we used a second mutant from within
the C4 coordination (Fig. 1E; C461S) where we mutated Cys461
to Ser. Analysis of this mutant demonstrated that it was also
more potent than theMDM2C478Smutant. These results sug-
gest that the difference in activity of the RING mutants is
unlikely to be due primarily to the choice of the substitution
residue.
To determine if endogenous p53-responsive promoters
respond to theMDM2RING domainmutant proteins in a sim-
ilar way to that observed using p53-responsive reporter con-
structs we used BAX protein expression as a measure of its
promoter activity, because BAX is a well characterized target
for p53 (31). For this assay we used MCF7 cells because they
have a wild-type p53 pathway. Fig. 1F shows that BAX protein
levels are unaffected by the expression of wtMDM2 at the con-
centrations used in the experiment (Fig. 1F, lanes 2–4), how-
ever under the same conditions theMDM2C464Amutant sup-
pressed BAX protein expression even at the lowest amount
used (lanes 8–10), and consistent with the reporter assays, the
MDM2C478Smutant had intermediate activity, because it sup-
pressed BAX protein expression when present at the highest
amount (lane 7).
Together the data presented above suggest that mutation of
residues within the RING finger domain that directly affect
MDM2 E3-ligase activity facilitate transrepression of p53 tran-
scriptional activity. In contrast, loss of MDM2molecular chap-
erone activity in the ATP-binding mutant (Lys454A) had no
effect on transrepression of p53. Further, the data demonstrate
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that MDM2 E3-ligase activity can be completely uncoupled
from its ability to repress p53 transcription.
The MDM2 Hydrophobic Pocket but Not the Acid Domain Is
Required for Efficient Transrepression of p53—Previous studies
have suggested that the hydrophobic pocket of MDM2 is criti-
cal for its transrepressor activity (15, 28), however these studies
were carried out before the complexity of the interaction
between MDM2 and p53 was fully appreciated. Because the
acid domain of MDM2 is now known to bind to the BOX-V
domain of p53 (16, 18) we sought to use MDM2 deletion
mutants to determine which interactions were salient for
MDM2-mediated transrepression. To investigate the influence
of MDM2 domain structure on p53 transrepression we used
mutant forms of murine MDM2 where one or other of the two
known p53 interacting domains had been deleted (Fig. 2A,
MDM2N and MDM2Ac). MDM2N prevents the interac-
tion between the transactivation domain of p53 (BOX-I) and
the hydrophobic pocket in the N terminus of MDM2 (14),
whereas the MDM2Ac precludes binding of the core domain
of p53 (BOX-V) and the acid domain ofMDM2 that is essential
for MDM2-mediated ubiquitination of p53 (16).
When the deletion mutants were analyzed in the p53-re-
porter assay (Fig. 2B) loss of the hydrophobic pocket essentially
inactivated MDM2 as a transrepressor of p53-mediated tran-
scription although expressed at a similar level to the wt protein
(Fig. 2C), whereas deletion of the acid domain did not have a
major impact on this activity of MDM2. The data suggest that
the interaction between the acid domain of MDM2 and the
BOX-V region of the p53 core domain is not essential for
MDM2 mediated transrepression, whereas binding of the
hydrophobic pocket to the BOX-I transactivation domain of
p53 is absolutely required because the Nmutant is essentially
dead in this assay. Together with data in the previous section
our results suggest that RING domain mutants that loose the
ability to ubiquitinate p53 but gain p53 repressor activity do so,
most likely, through modulation of the MDM2-hydrophobic
pocket: p53-BOX-I interaction.
RING Mutations Affect the Efficacy of Nutlin as an Inhibitor
of MDM2-mediated Repression of p53—The data presented
above establish that the hydrophobic pocket ofMDM2 is essen-
tial for transrepression of p53 (Fig. 2B) and that the ability of
MDM2 to transrepress p53-dependent transcription can be
uncoupled from MDM2 E3-ligase activity (Fig. 1C). Further-
more, the C2H2C4RINGmutants have a gain of transrepressor
activity when compared with the wt protein (Fig. 1C). To fur-
ther investigate the link between hydrophobic pocket binding
andRINGdomain functionwe used the cell-permeableMDM2
hydrophobic pocket binding molecule Nutlin as a tool
(32, 33).
We have previously suggested that Nutlin most likely
functions as an anticancer agent by affecting the ability of
MDM2 to act as a transrepressor of p53 transcription rather
than as an inhibitor ofMDM2-dependent p53 ubiquitination
(16). This hypothesis was based on observations, confirmed
here, that Nutlin is not able to inhibit the ubiquitination of
p53 in vitro using purified proteins (Fig. 3A) and that the
addition of Nutlin to A375 cells does not decrease the num-
ber of modified p53 forms detected (Fig. 3B). In fact in the
current experiments we show that an increase in p53 modi-
fication was proportionate to increases in total p53 protein
levels (see Fig. 5B, upper panel) and to the activation of p53,
as assessed by an increase in p21 protein levels (Fig. 3B, lower
panel). Together these results suggest that modification of
existing or newly synthesized p53 protein continues in the
presence of Nutlin.
If the above hypothesis is correct we would predict that
Nutlin binding to MDM2 would be sufficient to relieve tran-
srepression imposed by both wt and E3-inactive MDM2 pro-
tein. Using the p53-reporter assay the ability of Nutlin to
reverse transrepression imposed by a fixed amount of wt
MDM2 was shown to be efficient (Fig. 3C). Furthermore,
Nutlin had a striking effect on the transrepressor activity of
the Cys478S protein with p53 activity recovering to near the
level seen in the absence of MDM2. This result lends strong
support to the idea that Nutlin-dependent inhibition of
MDM2 as a transrepressor occurs independently of MDM2
E3-ligase function and that this could be sufficient to explain
the activating effect of Nutlin on p53.
Interestingly, although Nutlin was active against the
Cys478S MDM2 mutant protein it had only weak activity
against the Cys464A protein and even at 14 M Nutlin did not
inhibit this mutant. To confirm this result using a different
assay system we looked at the ability of Nutlin to overcome
wt and mutant MDM2-imposed transrepression of an
endogenous p53 promoter using p21 protein levels as a
downstream readout for transfected p53 (Fig. 3,D and E). An
amount of transfected MDM2 wt and mutant constructs was
chosen that gave maximal repression of endogenous p21
FIGURE 1. Mutation of the C2H2C4 RING gives a gain of MDM2 transrepression. A, schematic showing the RING finger domain of MDM2. The zinc
conjugating residues are highlighted and underlined, the ATP binding site is shaded gray, and the residues picked out (above) are those that were mutated to
generate the panel of mutants studied. B, immunoblot of p53 from p53/MDM2/mouse embryonic fibroblasts transfected with p53 (150 ng) and MDM2
(wt and mutant constructs as indicated;150 and 250 ng) plus His-Ub (200 ng). His-conjugated proteins were isolated using nickel-agarose and analyzed on a
4–12% gradient gel. p53 was detected using DO-1. The data are representative of two independent experiments. In C: upper panel, H1299 cells were trans-
fected with p53 alone (150 ng) or with a titration (75, 150, 300, 400, and 550 ng) of MDM2wt, MDM2K454A, MDM2C464A, or MDM2C478S plus the reporter
plasmids. Total DNAwas normalized using the vector control, and c is a vector only control. Post transfection (24 h) the Dual Luciferase Assay was performed.
The results are normalizedby expressingp21-Luciferase/Renilla activity in relative light units (RLU) and are themean S.D. (lower panel). Immunoblot showing
the levels of p53 with MDM2wt andmutant proteins, p53 was detected using DO-1 andMDM2 using 2A10.D, as above except that the cells were transfected
with ap53 titration (75, 150, and300ng) aloneor in thepresenceof a fixed concentrationofwt andmutantMDM2as indicated (400ng). Thevector-only control
is shown as c, and total DNA was normalized as above the data are representative of two individual experiments. E, schematic depicting zinc coordination
scheme of MDM2 (left panel). The key residues that were mutated are highlighted. The histogram represents data obtained from Dual Luciferase Assay
carried out as described above, with MDM2wt MDM2C478S and MDM2C461S. F, MCF7 cells were transfected with plasmids encoding MDM2WT,
MDM2C464A, and MDM2C478S (0–4 g). Total DNA amount was normalized using vector control. Twenty-four hours post transfection immunoblot
analysis was carried out, p53, MDM2, and BAXwere detected usingDO-1, 2A10, and anti-BAX, respectively. The results are representative of at least three
independent experiments.
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protein expression in H1299 cells (p21 levels decreased by
80%), Nutlin was then added to the cells in a titrative man-
ner, and the effect on p21 levels was determined. Quantita-
tion of the data generated in Fig. 3D shows that Nutlin can
relieve transrepression imposed by both the wt and Cys478S
mutant forms of MDM2 at the lowest concentration used
FIGURE 2. Thehydrophobic pocket ofMDM2 is essential for transrepression of p53.A, a schematic showingmurineMDM2deletion constructs. MDM2N
is missing the MDM2 hydrophobic pocket, which binds the BOX-I domain of p53, and MDM2 Ac does not have the acid domain, which binds the BOX-V
domain of p53. B, H1299 cells were transfectedwith p53 alone (150 ng) or with a titration (75, 150, 300, and 550 ng) of MDM2wt, MDM2N, or MDM2Ac plus
the reporter plasmids. Total DNA was normalized using the vector control. Post transfection (24 h) the Dual Luciferase Assay was performed. The results are
normalized by expressing p21-Luciferase/Renilla activity in relative light units (RLU), are the mean  S.D., and c is the vector-only control. C, immunoblot
showing the levels of mycMDM2wt andmycMDM2N detected using 2A10 (top panel) and anti-myc antibody (bottom panel), andMDM2Ac detected using
2A10 (top right panel).
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(1.5 M). However at 1.5 M, Nutlin had no measurable
effect on the levels of p21 protein in the presence of
MDM2C464A, in fact it required 7 M Nutlin to relief tran-
srepression by the Cys464A protein on p21 protein
expression.
The differential effect of Nutlin, dependent on the status of
the C2H2C4 RING structure, suggests that the introduction of
mutations that directly impact on RING structure can differen-
tially impact on the affinity or availability of MDM2’s hydro-
phobic pocket for p53 BOX-I binding.
FIGURE 3. The efficacy of Nutlin in cells is dependent on the C2H2H4 RING. A, ubiquitination reactions were assembled with p53, E1, E2, andMDM2 in the
presenceor absence (c) of eitherNutlin or BOX-I peptide (0, 10, 20, 40, and60M). Ubiquitinationwas analyzedby immunoblot usinga4–12%gradient gel, p53
was detected using DO-1. Unmodified (p53) and ubiquitinated p53 (Ub-p53) are shown. The data are representative of at least four separate experiments.
B, Nutlin (10 M) was added to A375 cells, and they were harvested over a 24-h time course (0, 1, 2, 3, 4, 6, 8, 12, and 24 h). The lysates were analyzed by
immunoblot using either a 4–12%gradient gel (upper panel) or a 15% SDS-PAGE gel (lower panel) p53was detected using DO-1 and p21 using AB-1. Modified
forms of p53 are given as Ub-p53. The data are representative of three such experiments. C, H1299 cells were transfected with p53 alone (150 ng) or together
with MDM2 (400 ng) after 24 h Nutlin (0, 1.5, 3, 5, and 14 M) was added, and the incubation continued for a further 6 h. Total DNA was normalized using the
vector control. The cells were harvested and theDual Luciferase Assaywas performed. The results are normalized by expressing p21-Luciferase/Renilla activity
in relative light units (RLU) and are the mean  S.D., and c is the vector-only control. A DMSO control is included for the Nutlin carrier. D, H1299 cells were
transfected with p53 alone (150 ng) or together with (300 ng) of MDM2wt, MDM2C464A, or MDM2C478S. Total DNAwas normalized using the vector control
(c). Post transfection (24 h) cells were treated with Nutlin (0, 1.5, 3, 5, and 14M) for a further 6 h. Immunoblot analysis of MDM2, p53, and p21 was carried out
using 2A10, DO-1, and Ab-1, respectively. E, densitometry analysis of the p21 immunoblot; p21 levels are given as a percentage of protein detected in the
presence of p53 alone.
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MDM2Cys RING FingerMutant Proteins Bind with a Higher
Affinity to the Transactivation Domain of p53—The cell-based
experiments described above show that (i) C2H2C4 RING
mutants have a gain of transrepressor activity and (ii) the
hydrophobic pocket, but not the acid domain, is essential for
MDM2 repressor activity. These results suggested to us that the
affinity of the hydrophobic pocket for the BOX-I domain of p53
might be sufficient to dictate the potency of MDM2 as a tran-
srepressor and may also determine the efficacy of hydrophobic
pocket binding drugs such as Nutlin.
If the above hypothesis is correct we would expect the
C2H2C4RINGdomainMDM2mutant proteins to bind BOX-I
with a higher affinity than thewild-type protein. To address this
we first purified full-length untagged humanMDM2, as well as
theCys464A andCys478SmutantMDM2proteins from anE. coli
expression system. The protein concentrations were normal-
ized and the quantitation was confirmed using an enzyme-
linked immunosorbent assay (Fig. 4A). E3-ligase activity was
assayed using a purified assay system (16) and as expected
(based on the results presented in Fig. 1B), whereas the wt pro-
tein was an active E3-ligase, neither the Cys464A nor the Cys478S
mutant were able to mediate ubiquitination of p53 (Fig. 4B).
Next the ability of the proteins to bind to full-length purified
p53 was determined (Fig. 4C). In this assay a constant amount
of full-length untagged p53, purified form E. coli, was captured
onto microtiter wells and incubated with a titration of wt or
mutant MDM2 protein. Following extensive washing bound
MDM2was detected using amonoclonal antibody (2A10). This
showed that both of the MDM2 C2H2C4 mutant proteins
bound with a higher affinity to full-length p53 than did wt
MDM2, however, consistent with its lower I0.5 in the transre-
pressor assay (Fig. 1C), the Cys464Amutant bound better to p53
than the Cys478S mutant protein.
Although the interaction between the acid domain of
MDM2 and the BOX-V domain of p53 is not essential for
MDM2 mediated transrepression (Fig. 2B) it is likely to play
a role in binding of MDM2 to full-length p53 protein (16).
Binding to the isolated BOX-I domain was therefore used to
determine whether the increase in affinity of the Cys464A and
Cys478S mutants for full-length p53 reflected a change in
affinity for the p53 BOX-I domain. Binding of wt and the
C2H2C4 mutant MDM2 proteins to a peptide based on the
BOX-I domain of p53, or to an optimized hydrophobic
pocket binding peptide, 12.1 (34), was determined. Biotiny-
lated BOX-I domain or 12.1 peptide were immobilized on
streptavidin-coated wells and incubated with a titration of
wt MDM2 or the two C2H2C4 mutant proteins. Consistent
with the data presented above, showing that the mutants
bind better to full-length p53, both the Cys464A and Cys478S
proteins bound with a higher affinity to BOX-I and 12.1 than
wt MDM2 protein. Mirroring its decreased I0.5 for transre-
pression and increased affinity for full-length p53 the
Cys464A mutant consistently bound better to BOX-I or the
BOX-I mimetic (12.1) than the Cys478 mutant protein.
The data presented above suggest that the increased transre-
pressor activity of the MDM2 C2H2C4 RING mutants is
dictated by an increase in the affinity of their hydrophobic
pockets for the BOX-I transactivation domain of p53.
TheMDM2 RINGMutant Proteins Differ in Their Sensitivity
to the Hydrophobic Pocket Binding Drug Nutlin—To determine
whether the differential effect ofNutlin on theC2H2C4MDM2
mutants observed in a cellular environment represented a
quantitative difference in the affinity of the mutants for Nutlin
binding, we determined the ability of Nutlin to compete with
BOX-I for binding to MDM2. In this assay equal amounts of
biotinylated BOX-I peptide were captured onto streptavidin-
coatedmicrotiterwells and incubatedwith a fixed amount ofwt
or mutantMDM2 in the presence of increasing Nutlin concen-
trations (Fig. 5A). Consistent with the results observed in cells
(Fig. 3C) this assay demonstrated an apparent difference in the
ability of the RING mutants to bind Nutlin, suggesting that
mutations within the C2H2C4 structure have a direct influence
on Nutlin binding that is not mediated by other cellular pro-
teins. Thus, Nutlin is a weak inhibitor of BOX-I binding to the
Cys464A mutant, relative to wild-type MDM2 protein, with an
I0.5 4 higher than wt MDM2. This suggests that the Cys464A
protein has a lower affinity for Nutlin than the wild-type pro-
tein and binds with a higher affinity to BOX-I resulting in pref-
erential BOX-I binding. Conversely, the Cys478S mutant
appears to bind Nutlin with a higher affinity than the wt and
Cys464A proteins. Thus, in this case Nutlin competes more eas-
ilywithBOX-I for binding to the hydrophobic pocket. Todeter-
mine if the differences observed in Nutlin binding are reflected
in the ability of Nutlin to disrupt the interaction between full-
length p53 and MDM2 the following experiment was per-
formed. Full-length p53 was coated onto the microtiter well
and incubated with a titration of MDM2 in the presence of
various fixed concentrations of Nutlin (Fig. 5B; 2.5, 5, and 10
M). Again there was a clear difference in Nutlin-dependent
disruption of full-length p53 binding to the MDM2 proteins,
with the p53-Cys478S mutant complex showing increased Nut-
lin sensitivity compared with the p53-Cys464A and the p53-
MDM2wt interactions. Once again this suggests that the
Cys478S mutant has a higher affinity for Nutlin than does the
Cys464A protein.
In conclusion, although both the Cys464A and Cys478S pro-
teins bind with a higher affinity to hydrophobic pocket inter-
acting ligands than the wt protein, resulting in a gain of tran-
srepressor activity (Fig. 2C), they do so differentially. Thus,
whereas the Cys478S protein binds preferentially to Nutlin, the
Cys464A protein binds with a higher affinity to BOX-I (Fig. 5)
resulting in differential Nutlin sensitivity in cells (Fig. 2C).
Moreover, mutations within the zinc coordinating structure of
the RING are not synonymous.
RING-generated Conformational Changes in MDM2 Are
Transmitted to the Hydrophobic Pocket through the Central
Domain—To support our hypothesis that hydrophobic pocket
affinity can be modulated by the RING domain, evidence of a
RING-dependent conformational change in full-lengthMDM2
was sought. Firstly, limited proteolysis was used to probe for
changes in the accessibility of trypsin cleavage sites in the
MDM2 Cys mutants verses the wt protein. Purified wt or
mutant MDM2 was incubated with trypsin at a ratio of 1:100
(protein) for up to 30 min, the samples were then analyzed by
gradient SDS-PAGE/immunoblot and cleavage fragments
identified using a mixture of MDM2 monoclonal antibodies
RING Finger Domain in Control of MDM2
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FIGURE 4. C2H2C4 mutant MDM2 binds with a higher affinity to p53. A, to check the accuracy of protein normalization for the purified MDM2wt,
MDM2C464A, and MDM2C478S proteins an enzyme-linked immunosorbent assay was performed in which a titration of MDM2 protein was coated onto
the microtiter plate wells, following extensive washing, and MDM2wt and mutant protein levels were detected using 2A10. B, ubiquitination reactions
were assembled with p53, E1, E2, and MDM2 wt or mutant proteins as indicated. Ubiquitination was analyzed by immunoblot using a 4–12% gradient
gel, p53 was detected using DO-1. Unmodified (p53) and ubiquitinated p53 (Ub-p53) is shown. C, p53 (100 ng/well) was coated ontomicrotiter wells and
incubated with wt or mutant MDM2 as indicated. MDM2 binding was detected using 2A10 and is expressed as relative light units (RLU) against the
MDM2 amount. The experiment is representative of three independent experiments where each condition was carried out in duplicate. In the schematic
the detecting antibody 2A10 is depicted. D, BOX-I (upper panel) or 12.1 (lower panel) peptides (5 M) were captured onto streptavidin-coated wells, and
MDM2 binding was determined as described in C. In the schematic BOX-I/12.1 are depicted and the detecting antibody is 2A10.
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(Fig. 6B). The results show that the
wt protein rapidly formed (within 5
min) a stable core comprising bands
1, 2, and 3, which was maintained
throughout the course of the exper-
iment. Although the MDM2C464A
mutant initially formed a similar
banding pattern to the wt protein,
with bands 1, 2, and 3 being
detected, it was then further pro-
cessed so that by 15min a new stable
pattern had emerged comprising
bands 2, 3, 4, and 5 with band 1
no longer being detected. Consis-
tent with earlier results the
MDM2C478S mutant appeared to
be intermediate between wt and the
Cys464A protein as at 30 min all five
bands were readily detected. These
results suggest that the Cys464A and
Cys478S mutants have a different
conformation to the wt protein
leading to the exposure of trypsin-
sensitive cleavage sites that are not
accessible in wt MDM2.
Further support for a difference
in conformation between the RING
mutants and wt MDM2 was pro-
vided by investigating the intrinsic
fluorescence properties of the pro-
tein (Fig. 6, C and D). Although all
aromatic amino acids can contrib-
ute to protein fluorescence, trypto-
phan is the dominant intrinsic flu-
orophore.MDM2 contains a total of
four tryptophan residues (Fig. 6A)
located in the central region of the
protein, in and around the acid
domain. Because the emission
observed reflects the average envi-
ronment surrounding each individ-
ual tryptophan and the tryptophans
within MDM2 are not in identical
local environments, each of these
residues will contribute unequally
to the emission spectrum. The max
of the emission spectrum of a tryp-
tophan will be shifted to longer
wavelengths (i.e. red-shift) if it is
involved in hydrogen bonding
and/or is exposed to buffer relative
to the lower wavelength max (blue
shift) of a tryptophan buried within
the hydrophobic core of the protein.
Fig. 6C compares the emission fluo-
rescence spectra of MDM2 wt and
the twoCysmutants. For both of the
mutant proteins we observe a red
FIGURE 5. Nutlin has a differential effect on the C2H2H4MDM2mutants. A, a schematic (left panel) shows
the assay format with BOX-I peptide Nutlin and the detecting antibody in blue. Right panel, BOX-1 peptide (5
M)was captured on streptavidin-coatedwells and incubatedwith the indicated formofMDM2 (50 ng), which
had been preincubated (5 min) with a titration of Nutlin (M). MDM2 binding was detected using 2A10 and is
given as relative binding expressed as a percentage where 100% binding is that measured in the absence of
Nutlin. B, p53 protein (100 ng/well) was coated onto microtiter wells and incubated with a titration of wt and
mutant MDM2 as indicated. The MDM2 had been preincubated with Nutlin (2.5, 5, and 10 M as indicated).
MDM2 binding was detected using 2A10 and is normalized to maximal binding to p53 in the presence of
saturating amounts of each mutant in %. The experiment is representative of at least three independent
experiments where each condition was carried out in duplicate. In the schematic the detecting antibody 2A10
and Nutlin are depicted.
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FIGURE 6. Conformational differences between wt and RING domain mutants of MDM2. A, a schematic representation of MDM2 showing the
epitopes for 3G5 and 2A10; the position of the 4 tryptophan residues inMDM2 ismarked. B, immunoblot showingwt ormutant forms ofMDM2 following
limited proteolysis with trypsin. The blot was developed using a mixture of the MDM2monoclonal antibodies 2A10, 4B2, 3G5, and SMP14. The numbers
are used to label the banding pattern; time points used were 0, 5, 10, 15, 20, and 30 min. The data are representative of three separate experiments.
C, resolution of fluorescence emission spectra of MDM2wt (white) and theMDM2C464A (brown) andMDM2C478S (blue) RINGmutants. The spectra were
corrected for associated buffer background signals. D, maxima with corresponding wavelength of MDM2 fluorescence emission spectra. The values
were calculated with mathematical n-polynomial based algorithm, where R2  0.999. E, as in B except the time course was 0, 5, and 20 min. The blots
were developed using 2A10 (upper panel) and 3G5 (lower panel). F, localization of the 3G5 antibody epitope within the MDM2 hydrophobic pocket
(pocket shown in ribbon representation, colored gold). Nutlin-3 bound to the pocket in stick representation (chlorine in green, carbon in gray, nitrogen in
blue, and oxygen in red). The epitope of 3G5 antibody consists of four critical residues; Leu66, Tyr67, Asp68, and Glu69, surrounded by trypsin cleavable Lys
and Arg residues (highlighted in purple). This figure was prepared using PyMOL (W. L. DeLano (2002) PyMOL, DeLano Scientific, San Carlos, CA), and
structural data were from file 1TTV-RCSB PDB.
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shift with max at 349–349.5 nm in contrast to that of the wt
protein of max at 343 nm (Fig. 6D). Moreover the differential
quenching of the emission spectrum (Fig. 6C) for the two
mutants indicates that their conformation changes are not
equivalent. Thus, the data show differences in conformation
between wt and mutant forms of MDM2 and between the two
mutants. The intrinsic fluorescence measurements are there-
fore consistent with the partial proteolytic digestion data (Fig.
6B) and with the differential binding affinity of the Cys464A and
Cys478S mutants for BOX-I and Nutlin (Figs. 4 and 5).
The experiments presented above using limited proteolysis
(Fig. 6B) and intrinsic fluorescence (Fig. 6C) suggest that the
introduction of point mutations in key RING domain Cys resi-
dues generates a measurable conformational change in full-
length MDM2 protein. To establish whether these conforma-
tional changes have a direct impact on the structure of the
hydrophobic pocket we employed a monoclonal antibody
(3G5), which binds to an epitope in the center of the hydropho-
bic pocket (Fig. 6A) (35). Using limited proteolysis we deter-
mined whether changes in the RING domain had an effect on
the ability of 3G5 to bind to the hydrophobic pocket ofMDM2.
As a control for this experiment we used the monoclonal anti-
body 2A10, which has been mapped to two epitopes within the
central and C-terminal domains of MDM2 (Fig. 6A). The 2A10
data (Fig. 6E, upper panel) suggests that the core fragments
identified in Fig. 6B (in particular bands 2–4) are comprised
largely of the central domain of MDM2 together with C-termi-
nal truncations. In contrast 3G5 (Fig. 6E, lower panel) suggests
that the hydrophobic pocket is rapidly cleaved from the core of
MDM2 and that its removal generates a fast migrating 3G5
reactive product (band 6). The MDM2C478S mutant appears
to be more sensitive to this type of cleavage, because 3G5-pos-
itive full-length protein is lost more rapidly than it is for wt
MDM2. Of particular interest in this assay is theMDM2C464A
mutant, as incubation of this protein leads to a dramatic loss of
the 3G5 epitope suggesting that the hydrophobic pocket in this
protein ismore “relaxed” and thereforemore accessible to tryp-
sin digestion duringwhich the 3G5 epitope is cleaved leading to
a loss of antibody binding.
Together the data presented in this section support the con-
clusion that the RING domain of MDM2 can influence the
activity of the N-terminal hydrophobic pocket by producing
long range conformational changes that are transmitted
through the central acid core ofMDM2 andwhich lead to vary-
ing degrees of relaxation in the hydrophobic pocket.
DISCUSSION
Studies addressing how MDM2 structure supports its func-
tional diversity have begun to provide insight into the proteins
conformational flexibility. Thus, a picture is immerging of
interdependent functional domains linked through changes in
conformation, emphasizing the need to study the domain
structure of MDM2 within the context of the whole protein. In
the current study we have used point mutations within the
RING finger domain to uncover cross-talk between the C ter-
minus and interactions taking place at the N-terminal hydro-
phobic pocket of MDM2. Our results show that RING-medi-
ated allosteric modulation of the hydrophobic pocket has
implications for bothMDM2 transrepressor activity and for the
efficacy of MDM2-targeted therapy (Fig. 7).
We previously described a link between the hydrophobic
pocket of MDM2 and its acid domain (16). In this case occupa-
tion of the hydrophobic pocket promoted conformational
changes in MDM2 that favored acid domain binding to a ubiq-
uitination signal in the core DNA binding domain of p53. This
allostericmechanismpromotesMDM2 function as anE3-ubiq-
uitin ligase by stabilizing a low affinity interaction between the
BOX-V domain of p53 and the acid domain of MDM2. The
current data add to this model for the regulation of oneMDM2
domain throughmodulation of a second by demonstrating that
the RING finger domain, and more specifically residues
required to form the C2H2C4 RING structure, can alloster-
ically modulate hydrophobic pocket interactions. In this case
the result is an increase in the affinity of the hydrophobic
pocket, which produces a gain in transrepressor function in
FIGURE 7.Model for the allosteric regulation of MDM2. Our data suggest
the binding of interacting proteins and ligands or post-translational modifi-
cation within the RING domain of MDM2 (a), which affect RING architecture,
will cause conformational changes leading to changes in the affinity of the
hydrophobic pocket for BOX-I domain of p53 and other ligands. This can
result in formation of a transcriptionally inactive complex (b), or, basedonour
previous studies (16), could result in a transition complex (c)wherehydropho-
bic pocket binding leads the acid domain to bind to the core BOX-V site in
p53-signaling p53 ubiquitination (d).
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cells. Interestingly, mutations of Cys464 and Cys478 residues are
not equivalent in terms of their effect on the hydrophobic
pocket. Thus, although bothmutants display increased binding
to the BOX-I domain of p53 (Fig. 4), the Cys478S mutant binds
Nutlin in preference to BOX-I, whereas the Cys464A protein
preferentially binds to BOX-I (Fig. 5).
Structural and computational analysis of the MDM2 hydro-
phobic pocket interaction with p53 has revealed that this
domain has a high degree of plasticity and has suggested that
the shape of the binding cleft can change significantly (36, 37).
A mechanism has been proposed where binding to the BOX-I
domain of p53 requires a progressive opening up of the binding
cleft to reveal a hydrophobic interface. p53 binding then pro-
ceeds through an intermediate complex where the cleft gradu-
ally adopts amore open conformation eventually accommodat-
ing Thr18–Asp29 of BOX-I. Based on this type of study it has
been hypothesized that the cleft has enough plasticity to allow a
range of low energy states rather than a single “open” or
“closed” conformation. As a result the pocket can accommo-
date a range of peptides and small molecules that might not
have any obvious structural similarity (32, 36–39). It is likely
therefore that the differential binding preferences of our two
Cys mutants are a result of different degrees of cleft accessibil-
ity. This hypothesis is supported by data showing that, although
the Cys464A and Cys478S mutant proteins both adopt a different
stable conformation from the wt protein (Fig. 6), their confor-
mation is not equivalent. The intrinsic fluorescence of trypto-
phan residues within the central domain of the Cys478S mutant
is quenched relative to those in the Cys464A mutant, suggesting
that they aremore solvent-exposed or are involved in additional
interactions with nearby residues. Further evidence for a differ-
ence in the conformation of the hydrophobic cleft dependent
on the status of the RING domain comes from the use of the
monoclonal antibody 3G5 to probe for differences in confor-
mation following limited tryptic digestion (Fig. 6E). This anti-
body recognizes an epitope in the hydrophobic pocket of
MDM2, where residues 66LYDE69 are essential but not suffi-
cient for binding, i.e. peptides containing the LYDE motif but
not other surrounding residues are not sufficient for antibody
recognition (35). The LYDE motif maps to a loop structure in
the hydrophobic pocket that lies between two of the -helical
structures that form the BOX-I binding cleft (Fig. 6F) and is
flanked by lysine and arginine residues that provide tryptic cut
sites when exposed (61IMTKRLYDEKQQHIV75). Our data
show that the LYDE motif is more accessible in the Cys464A
mutant than in the wt or the Cys478S protein (Fig. 6F), suggest-
ing that the cleft ismore relaxed and thereforemore readily able
to accommodate the BOX-I peptide leading to an increase in
BOX-I affinity.
Our data, showing thatmutations in theC-terminal C2H2C4
RING of MDM2 can allosterically modulate not only the affin-
ity of the hydrophobic pocket but also its specificity (Fig. 5),
suggest that in cells the binding of interacting proteins and/or
ligands to the RING is likely to impact on bothMDM2 transre-
pressor activity and on the efficacy of pocket binding drugs in
tumor cells (Fig. 6). This hypothesis is supported by data show-
ing that binding of ligands such as zinc and ATP to the RING
finger domain ofMDM2 generate conformational changes (17,
23). In fact, we have previously shown that zinc binding can
affect the interaction ofMDM2with the BOX-I domain of p53;
in this case zinc binding leads to a decrease in BOX-I binding
(17, 23). Together with our current data this suggests thatmod-
ulation of the RINGdomain has the potential to both negatively
and positively regulate binding of BOX-I to the hydrophobic
pocket. As the Cys mutants used in the current study are E3-li-
gase dead, it is not possible to determine if C2H2C4 RING
interacting factors could also promote MDM2 E3-ligase activ-
ity, because increased binding to hydrophobic pocket binding
ligands could potentially favor acid domain binding to the
BOX-V domain of p53 signaling ubiquitination (16). Thus, it
will be interesting to determine whether RING domain-inter-
acting factors, or modifications, such as acetylation (40), within
the RING domain act in a concerted manner to promote both
transrepression and ubiquitination of p53 or whether changes
in RING conformation might act as a switch favoring one
MDM2 activity over another.
Recent genetic studies have suggested that the primary phys-
iological role of MDM2 is the regulation of p53 protein levels
mediated by its E3-ligase activity (41, 42). These experiments
were largely carried out in mouse embryonic fibroblasts and
developingmouse embryos whereMDM2 activity has been lost
or reduced and is therefore rate-limiting. However, this situa-
tion is unlikely to reflect the environment encountered in most
tumor cells. In fact current estimates suggest thatMDM2 levels
are elevated in10% of all human tumors (43) due for example
to enhanced translation or transcription in addition to amplifi-
cation of the MDM2 gene (44). In contrast to the studies in
non-transformed mouse cell models mentioned above work in
tumor cells endogenously overexpressing MDM2 protein sug-
gests that its ability to act as a transrepressor contributes signif-
icantly to the impaired p53-response seen in these cells. Thus,
in cells that are homozygous for a polymorphism (SNP309) that
enhances SP1-dependent MDM2 transcription the MDM2
protein is found in association with p53 resulting in transcrip-
tionally inactive complexes (25, 45). Depletion of MDM2 by
siRNA in these cells results in activation of p53-dependent
transcription in the absence of increase p53 protein levels sup-
porting the idea that, at least in some tumor cells, MDM2 acts
predominantly as a transrepressor of p53 function (25). Fur-
thermore, it has been demonstrated that tumor cells that do not
have increased MDM2 levels also operate an MDM2-depend-
entmechanism for controlling p53 transcription in the absence
of changes in p53 protein levels (46). Thus, the data presented
here, showing that C2H2C4 RINGmutants that loose E3-ubiq-
uitin ligase activity preferentially bind to p53 inhibiting its
transactivation activity, may be pertinent to the physiological
environment of a tumor cell where MDM2 is controlling p53
activity primarily through transrepression.
Wehave shown thatNutlin does not inhibitMDM2E3-ligase
activity neither in vitro nor in cell models (Fig. 3; 16). However,
despite its lack of E3-ligase inhibitory activity Nutlin can func-
tion in cells and animal models of cancer to activate p53 and to
elevate p53 protein levels (32, 33). Evidence presented here
showing that Nutlin can reverse transrepression imposed by
both the wild-type and the Cys478S mutated form of MDM2
suggests that it functions primarily by relieving MDM2-im-
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posed transrepression allowing binding to coactivators such as
p300. This conclusion is supported by the observation thatNut-
lin promotes rapid activation of p53-dependent transcription
before changes in p53 protein level are recorded (46). The fact
that Nutlin is proving to be an effective drug in somemodels of
human cancer provides further evidence for the role of MDM2
transrepressor activity in tumor development.
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